

The significance of autoantibodies against Î²2-glycoprotein

Blood

120, 266-274

DOI: [10.1182/blood-2012-03-378646](https://doi.org/10.1182/blood-2012-03-378646)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders. <i>Blood</i> , 2012, 120, 4134-4142.	1.4	6
2	Review: Viral infections and mechanisms of thrombosis and bleeding. <i>Journal of Medical Virology</i> , 2012, 84, 1680-1696.	5.0	252
3	Antiphospholipid antibodies: Evaluation of the thrombotic risk. <i>Thrombosis Research</i> , 2012, 130, S37-S40.	1.7	48
4	From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: Pathogenic mechanisms of the antiphospholipid syndrome. <i>Thrombosis Research</i> , 2013, 132, 319-326.	1.7	34
5	Antiphospholipid syndrome: Looking for a refocusing. <i>Thrombosis Research</i> , 2013, 131, S28-S31.	1.7	14
6	Dendritic cells: An important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases. <i>Clinical Immunology</i> , 2013, 146, 197-206.	3.2	30
7	Atomic force microscopy: High resolution dynamic imaging of cellular and molecular structure in health and disease. <i>Journal of Cellular Physiology</i> , 2013, 228, 1949-1955.	4.1	21
8	Vascular Endothelial Cell Function in Catastrophic Antiphospholipid Syndrome: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2013, 2013, 1-4.	0.4	4
9	Anti- β 2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. <i>Blood</i> , 2013, 122, 3808-3817.	1.4	36
10	Laboratory Diagnosis of Antiphospholipid Syndrome. <i>Southern Medical Journal</i> , 2013, 106, 439-446.	0.7	5
11	Obstetrical Antiphospholipid Syndrome: From the Pathogenesis to the Clinical and Therapeutic Implications. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-9.	3.3	27
12	Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	2.2	35
13	Clinical immunology – Autoimmunity in the Netherlands. <i>Immunology Letters</i> , 2014, 162, 134-140.	2.5	2
14	Cellular signaling by antiphospholipid antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 773-775.	3.8	6
15	Renal Transplantation Dramatically Reduces IgA Anti-beta-2-glycoprotein I Antibodies in Patients with Endstage Renal Disease. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	2.2	24
16	Lupus anticoagulant testing and anticoagulation do not mix: quantitation of discrepant results and potential approaches to reduce false positives. <i>British Journal of Haematology</i> , 2014, 167, 704-707.	2.5	18
17	A potential anti-coagulant role of complement factor H. <i>Molecular Immunology</i> , 2014, 59, 188-193.	2.2	21
18	Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. <i>Nature Reviews Neurology</i> , 2014, 10, 579-596.	10.1	219

#	ARTICLE	IF	CITATIONS
19	Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 910-920.	3.8	71
20	Contribution of anti- β 2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. <i>Rheumatology</i> , 2014, 53, 1215-1218.	1.9	30
21	Exámenes de laboratorio en las patologías articulares autoinmunes. <i>EMC - Aparato Locomotor</i> , 2014, 47, 1-14.	0.1	0
22	oxLDL/ β 2GPI/anti- β 2GPI complex induced macrophage differentiation to foam cell involving TLR4/NF-kappa B signal transduction pathway. <i>Thrombosis Research</i> , 2014, 134, 384-392.	1.7	22
23	Inhibition of thrombotic properties of persistent autoimmune anti- β 2GPI antibodies in the mouse model of antiphospholipid syndrome. <i>Blood</i> , 2014, 123, 1090-1097.	1.4	35
24	Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. <i>Blood</i> , 2014, 124, 611-622.	1.4	105
25	The Pathogenicity of Anti- β 2GPI-IgG Autoantibodies Depends on Fc Glycosylation. <i>Journal of Immunology Research</i> , 2015, 2015, 1-12.	2.2	33
26	The Infectious Origin of the Anti-Phospholipid Syndrome. , 2015, , 681-696.		0
27	Microparticles: Bridging the Gap between Autoimmunity and Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 413-422.	2.7	34
28	Detection of circulating immune complexes of human IgA and beta 2 glycoprotein I in patients with antiphospholipid syndrome symptomatology. <i>Journal of Immunological Methods</i> , 2015, 422, 51-58.	1.4	21
29	Association of Early Kidney Allograft Failure with Preformed IgA Antibodies to β 2-Glycoprotein I. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 735-745.	6.1	31
30	Hereditary and Acquired Thrombophilia in Splanchnic Vein Thrombosis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2015, 21, 521-526.	1.7	8
31	An A1A1 mutant with improved binding and inhibition of β 2GPI/antibody complexes in antiphospholipid syndrome. <i>FEBS Journal</i> , 2015, 282, 864-873.	4.7	7
32	The class I phosphoinositide 3-kinases $\hat{1}$ and $\hat{2}$ control antiphospholipid antibodies-induced platelet activation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1138-1146.	3.4	13
33	β 2GPI, Anti- β 2GPI Antibodies and Platelets: Key Players in the Antiphospholipid Syndrome. <i>Antibodies</i> , 2016, 5, 12.	2.5	25
34	Current Controversies in Lupus Anticoagulant Detection. <i>Antibodies</i> , 2016, 5, 22.	2.5	23
35	Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. <i>PLoS ONE</i> , 2016, 11, e0158757.	2.5	25
36	Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 675-684.	3.8	24

#	ARTICLE	IF	CITATIONS
37	Soluble analog of ApoER2 targeting beta2â€glycoprotein I in immune complexes counteracts hypertension in lupusâ€prone mice with spontaneous antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1298-1307.	3.8	5
38	Cofactorâ€independent human antiphospholipid antibodies induce venous thrombosis in mice. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1011-1020.	3.8	44
39	Pediatric Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2016, 11, 385-408.	0.1	0
40	Recurrent ventricular tachycardia and peripheral gangrene in a young child. <i>Indian Pediatrics</i> , 2016, 53, 815-821.	0.4	2
41	Distribution of antiphospholipid antibodies in a large population-based German cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1663-1670.	2.3	20
42	Thrombotic Primary Antiphospholipid Syndrome: the profile of antibody positivity in patients from North India. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 903-912.	1.9	9
43	Clinical implications of the detection of antibodies directed against domain 1 of Î²2-glycoprotein 1 in thrombotic antiphospholipid syndrome. <i>Thrombosis Research</i> , 2016, 148, 32-37.	1.7	5
44	Antiphospholipid Antibodies and the Risk of Stroke in Urban and Rural Tanzania. <i>Stroke</i> , 2016, 47, 2589-2595.	2.0	12
45	Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. <i>Scientific Reports</i> , 2016, 6, 36025.	3.3	83
46	Is leukocyte tissue factor the key to venous thrombosis in antiphospholipid syndrome?. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1008-1010.	3.8	2
48	Signs of impaired immunoregulation and enhanced effector T-cell responses in the primary antiphospholipid syndrome. <i>Lupus</i> , 2016, 25, 389-398.	1.6	14
49	A Study of Anti Beta-2 Glycoprotein I and Anti-Prothrombin Antibodies in Patients with Unexplained Recurrent Pregnancy Losses. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 198-201.	0.6	1
50	Anti-phospholipid Antibodies and Smoking: An Overview. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 53, 1-13.	6.5	20
51	Potential influences of complement factor H in autoimmune inflammatory and thrombotic disorders. <i>Molecular Immunology</i> , 2017, 84, 84-106.	2.2	22
53	Diagnosis and treatment of antiphospholipid syndrome in childhood: A review. <i>Blood Cells, Molecules, and Diseases</i> , 2017, 67, 34-40.	1.4	20
54	Antiphospholipid antibodyâ€induced cellular responses depend on epitope specificity : implications for treatment of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2367-2376.	3.8	25
55	Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's. <i>Autoimmunity Reviews</i> , 2017, 16, 1103-1108.	5.8	14
56	Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. <i>Science Signaling</i> , 2017, 10, .	3.6	40

#	ARTICLE	IF	CITATIONS
57	Anti-Î² ₂ Glycoprotein I Antibodies in Children with Rheumatologic Disorders. <i>Indian Journal of Clinical Biochemistry</i> , 2019, 34, 95-100.	1.9	3
58	Characteristics of patients diagnosed with renal vein thrombosis and glomerulopathy: a case series. <i>International Urology and Nephrology</i> , 2017, 49, 285-293.	1.4	4
59	The Laboratory Diagnosis of the Antiphospholipid Syndrome. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 8-14.	0.6	12
60	Venous thromboembolism related to cytomegalovirus infection. <i>Medicine (United States)</i> , 2017, 96, e9336.	1.0	11
61	Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops. <i>Antibodies</i> , 2017, 6, 8.	2.5	8
62	Implications of Antiphospholipid and Antineutrophilic Cytoplasmic Antibodies in the Context of Postinfectious Glomerulonephritis. <i>Case Reports in Medicine</i> , 2017, 2017, 1-3.	0.7	0
63	Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. <i>Blood</i> , 2018, 131, 2097-2110.	1.4	50
64	Standardization of autoimmune testing â€“ is it feasible?. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1734-1742.	2.3	14
65	Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. <i>Vaccine</i> , 2018, 36, 2604-2611.	3.8	47
66	Antiphospholipid syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 17103.	30.5	233
67	Effects of anti-Î² ₂ GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 380-389.	2.3	10
68	New Insights in the Pathophysiology of Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 475-482.	2.7	26
69	Further Investigations of the Effects of Anti-Î² ₂ GPI Antibodies on Collagen-Induced Platelet Aggregation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 1128-1133.	1.7	5
70	Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1548-1553.	1.2	30
71	Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective. <i>Thrombosis Research</i> , 2018, 169, 35-40.	1.7	31
72	Anti-Î² ₂ GPI/Î² ₂ GPI induces neutrophil extracellular traps formation to promote thrombogenesis via the TLR4/MyD88/MAPKs axis activation. <i>Neuropharmacology</i> , 2018, 138, 140-150.	4.1	36
73	Anti-domain 1 of beta2-glycoprotein I aids risk stratification in lupus anticoagulant-positive patients. <i>Clinical and Experimental Medicine</i> , 2019, 19, 339-345.	3.6	6
74	Platelet Activation by Antiphospholipid Antibodies Depends on Epitope Specificity and is Prevented by mTOR Inhibitors. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1147-1153.	3.4	22

#	ARTICLE	IF	CITATIONS
75	The Glycoprotein Ib-IX-V Complex. , 2019, , 193-211.		9
76	Cofactor-Independent Antiphospholipid Antibodies: Implications for Pathogenesis, Diagnosis, and Treatment of Antiphospholipid Syndrome. <i>Hamostaseologie</i> , 2019, 39, 188-194.	1.9	5
77	Endothelium structure and function in kidney health and disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 87-108.	9.6	292
78	New insight into antiphospholipid syndrome: antibodies to Î²2glycoprotein I-domain 5 fail to induce thrombi in rats. <i>Haematologica</i> , 2019, 104, 819-826.	3.5	40
80	Induction of tissue factor expression by anti-Î²2-glycoprotein I is mediated by tumor necrosis factor Î±. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 228-234.	2.1	7
81	Autoantibody Profiling in Plasma of Dengue Virusâ€“Infected Individuals. <i>Pathogens</i> , 2020, 9, 1060.	2.8	6
82	Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	491
83	In silico identification of new inhibitors for Î²eta-2-glycoprotein I as a major antigen in antiphospholipid antibody syndrome. <i>Journal of Molecular Modeling</i> , 2020, 26, 156.	1.8	6
84	The role of phosphatidylserine recognition receptors in multiple biological functions. <i>Cellular and Molecular Biology Letters</i> , 2020, 25, 23.	7.0	71
85	Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti-Îµphosphatidylâ€“serine/prothrombin antibodies to lupus anticoagulant activity. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1124-1132.	3.8	51
86	The antiphospholipid syndrome â€“ often overlooked cause of vascular occlusions?. <i>Journal of Internal Medicine</i> , 2020, 287, 349-372.	6.0	27
87	An update on the management of antiphospholipid syndrome. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091085.	2.7	26
88	Anti-Glycan Autoantibodies Induced by <i>Helicobacter pylori</i> as a Potential Risk Factor for Myocardial Infarction. <i>Frontiers in Immunology</i> , 2020, 11, 597.	4.8	6
89	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. <i>Cell Reports</i> , 2021, 34, 108620.	6.4	21
90	Potential mechanisms of cerebrovascular diseases in COVID-19 patients. <i>Journal of NeuroVirology</i> , 2021, 27, 35-51.	2.1	24
91	Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. <i>Scientific Reports</i> , 2021, 11, 4542.	3.3	3
92	Cardiolipin interacts with beta-2-glycoprotein I and forms an open conformationâ€“Mechanisms analyzed using hydrogen/deuterium exchange. <i>Protein Science</i> , 2021, 30, 927-939.	7.6	9
93	Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. <i>Lupus</i> , 2021, 30, 1289-1299.	1.6	6

#	ARTICLE	IF	CITATIONS
94	The antiphospholipid syndrome. <i>Revista Colombiana De Reumatología</i> , 2021, 28, 166-176.	0.1	0
95	An allosteric redox switch in domain V of β_2 -glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. <i>Journal of Biological Chemistry</i> , 2021, 297, 100890.	3.4	10
96	Protein Phosphatase 2A Activation Via ApoER2 in Trophoblasts Drives Preeclampsia in a Mouse Model of the Antiphospholipid Syndrome. <i>Circulation Research</i> , 2021, 129, 735-750.	4.5	10
98	Differential assay reactivity of immunoglobulin A anti- β_2 glycoprotein I antibodies: implications for the clinical interpretation of antiphospholipid antibody testing. <i>European Journal of Rheumatology</i> , 2015, 2, 135-138.	0.6	5
99	Cytomegalovirus-Associated Venous and Arterial Thrombotic Disease. <i>Cureus</i> , 2020, 12, e12161.	0.5	4
100	Postpartum Catastrophic Anti-Phospholipid Syndrome. <i>Sri Lankan Journal of Anaesthesiology</i> , 2015, 23, 83.	0.1	0
101	Antiphospholipid Antibody Syndrome in Childhood. , 2017, , 377-392.		0
102	Origin of Antiphospholipid Antibodies. , 2017, , 29-52.		1
104	Kidney damage associated with anti-phospholipid syndrome. <i>PoÄki</i> , 2019, 8, 161-173.	0.4	4
105	Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries. <i>Journal of Internal Medicine</i> , 2022, 291, 327-337.	6.0	3
106	Fc receptors gone wrong: A comprehensive review of their roles in autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2022, 21, 103016.	5.8	15
107	Neurocoagulation from a Mechanistic Point of View in the Central Nervous System. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 277-287.	2.7	4
108	Detection of IgA Antiphospholipid Antibodies Does not Improve Thrombotic Antiphospholipid Syndrome Classification: A two-Center Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210811.	1.7	3
109	Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 852777.	2.4	8
110	The Role of Autoantibody Testing in Modern Personalized Medicine. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 251-288.	6.5	3
111	IgG fractions from patients with antiphospholipid syndrome and systemic lupus erythematosus bind to platelets, but do not affect collagen-induced platelet activation. <i>Biotechnic and Histochemistry</i> , 2022, 97, 604-615.	1.3	0
112	Anti- β_2 -GPI Antibodies Induce Endothelial Cell Expression of Tissue Factor by LRP6 Signal Transduction Pathway Involving Lipid Rafts. <i>Cells</i> , 2022, 11, 1288.	4.1	4
113	Platelet- and endothelial-derived microparticles in the context of different antiphospholipid antibody profiles. <i>Lupus</i> , 2022, 31, 1328-1334.	1.6	5

#	ARTICLE	IF	CITATIONS
114	Thrombin generation assay and lupus anticoagulant synergically distinguish populations of patients with antiphospholipid antibodies. <i>Journal of Clinical Pathology</i> , 2023, 76, 839-846.	2.0	3
115	Plasminogen activator-coated nanobubbles targeting cellbound β_2 -glycoprotein I as a novel thrombus-specific thrombolytic strategy. <i>Haematologica</i> , 2023, 108, 1861-1872.	3.5	5
116	Circulating immune-complexes of IgG/IgM bound to β_2 -glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
117	Autoantibody profile in sarcoidosis, analysis from the GRADS sarcoidosis cohort. <i>PLoS ONE</i> , 2022, 17, e0274381.	2.5	2
118	Anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) increase the risk for thrombosis based on lupus anticoagulant positivity. <i>Clinical Biochemistry</i> , 2023, 112, 17-23.	1.9	2
119	Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome. <i>European Medical Journal Rheumatology</i> , 0, , 101-111.	0.0	3
120	Venous thromboembolism in viral diseases: A comprehensive literature review. <i>Health Science Reports</i> , 2023, 6, .	1.5	5
121	Effect of COVID-19 inactivated vaccine on peripheral blood anti- β_2 -GPI antibody and outcomes in vitro fertilization-embryo transplantation. <i>International Immunopharmacology</i> , 2023, 122, 110596.	3.8	1
122	The Infectious Origin of the Anti-Phospholipid Syndrome. , 2024, , 695-713.		0
123	Lipid-binding antiphospholipid antibodies: significance for pathophysiology and diagnosis of the antiphospholipid syndrome. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 0, , 1-18.	6.1	0
124	Taipan snake venom time has high sensitivity for lupus anticoagulants in non-anticoagulated, triple positive antiphospholipid syndrome patients. <i>International Journal of Laboratory Hematology</i> , 2024, 46, 538-545.	1.3	0
125	Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome. <i>Rheumatology</i> , 2024, 63, SI54-SI63.	1.9	1
126	The mystery of autoantibodies solved?. <i>Blood</i> , 2024, 143, 1065-1066.	1.4	0